Neuromod Devices, a medical-devices company, is looking to expand its Irish operations and create 50 jobs over the next five years.
The company is headquartered at University College Dublin’s NovaUCD centre for start-ups and innovative companies.
Neuromod Devices said it plans to facilitate the production of a number of new devices by filling 50 highly specialised roles to support its global aim of providing non-surgical neuromodulation treatments for chronic conditions.
In particular, these jobs will support the company’s latest device, mutebutton, a self-administered treatment to alleviate the symptoms of chronic tinnitus.
From 15 December, Irish tinnitus sufferers will be the first members of the public to be able to receive treatment via the new device. Patients will be given an appointment to have the device configured to their needs by a qualified audiologist.
Neuromod Devices CEO Dr Ross O’Neill is the developer of mutebutton.
“After four years of research and development, today Neuromod Devices is positioned to meet the unmet needs of tinnitus patients globally, with the launch of the mutebutton device,” said O’Neill.
“I am immensely proud of what we have achieved as a small Irish SME in just four years and this is in no small part thanks to the State support we have received from Enterprise Ireland and the NDRC.”
The next major step for the company is the release of its tinnitus aid to the European market in January 2015.
